The median OS improvement is anticipated to surpass one year ... "J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial" was originally created and published by Clinical ...

The SURPASS-ET trial (NCT04285086), evaluating ropeginterferon alfa-2b ... For the secondary end point, the JAK2 V617F allele burden decreased from 33.7% to 25.3% (-8.4%) in the ropeginterferon ...

Contributing to the German beauty company’s strong growth trajectory were its U.S. business and social media backing.

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...

Korea’s three mobile carriers face huge uncertainties in their efforts to reshape their portfolios for artificial ...

The trial will focus on evaluating the safety and ... and the market for its therapeutics is expected to surpass $14 billion by 2030. As there are currently no disease-modifying treatments ...

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), retaining the price target ...